Raka Jain
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Raka Jain has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
K. Mukherjee
2 shared publicationsKaushiki Mukherjee
National Drug Dependence Centre, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, Pin-110029, India
2 shared publicationsRajat Ray
2 shared publications- Anju Dhawan
National Drug Dependence Treatment Centre, All India Institute Of Medical Sciences, New Delhi, India
1 shared publication Davinder Mohan
Department of Psychiatry, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, Pin-110029, India
1 shared publication- Rajat Ray
National Drug Dependence Treatment Centre, All India Institute Of Medical Sciences, New Delhi, India
1 shared publication
Latest Publications
- 17 June 2011
- Vol. 54 (4) , 337-43
Comparison of self-reported benzodiazepine use and urinalysis among consecutive treatment seekers at a tertiary care drug dependence treatment centre.
Information provided by drug dependent patients might be incomplete and/or discrepant. Benzodiazepines are frequently abused, but not necessarily reported, even bythe treatment seeking population. The study aims to compare the self reported benzodiazepine use with a quick and effective urinalysis method. A total of 51 consecutive adult patients were included after an informed consent during their first visit to a tertiary care drug dependence treatment centre. The socio-demographic and clinical details were recorded on a semi-structured proforma. Patients were specifically asked for ever, current and recent benzodiazepine use and thereafter ten ml urine sample was collected to perform urinalysis with cassette test for benzodiazepines. The sample, predominantly males, had a mean age of 37.86 +/-10.46 years. The common primary drugs of use were heroin (52.9%), alcohol (23.5%) and other opioids (21.6%). Drug use was uninterrupted in most of users (72.5%) and ranged from one to forty years. The recent benzodiazepine use was reported by 21.6% of all users whereas urinalysis by cassette test was positive in 50.9% of the treatment seekers. Denial among users was 69.2% and denial among negative self report was 45%. A poor level of agreement (K) was found between results of self-report and urinalysis for all the treatment seekers. Self report of benzodiazepine use is highly questionable among treatment seekers. The urinalysis with cassette test is a quick objective method which is recommended for routine screening.
- 17 June 2011
- Vol. 54 (4) , 337-43
Comparison of self-reported benzodiazepine use and urinalysis among consecutive treatment seekers at a tertiary care drug dependence treatment centre.
Information provided by drug dependent patients might be incomplete and/or discrepant. Benzodiazepines are frequently abused, but not necessarily reported, even bythe treatment seeking population. The study aims to compare the self reported benzodiazepine use with a quick and effective urinalysis method. A total of 51 consecutive adult patients were included after an informed consent during their first visit to a tertiary care drug dependence treatment centre. The socio-demographic and clinical details were recorded on a semi-structured proforma. Patients were specifically asked for ever, current and recent benzodiazepine use and thereafter ten ml urine sample was collected to perform urinalysis with cassette test for benzodiazepines. The sample, predominantly males, had a mean age of 37.86 +/-10.46 years. The common primary drugs of use were heroin (52.9%), alcohol (23.5%) and other opioids (21.6%). Drug use was uninterrupted in most of users (72.5%) and ranged from one to forty years. The recent benzodiazepine use was reported by 21.6% of all users whereas urinalysis by cassette test was positive in 50.9% of the treatment seekers. Denial among users was 69.2% and denial among negative self report was 45%. A poor level of agreement (K) was found between results of self-report and urinalysis for all the treatment seekers. Self report of benzodiazepine use is highly questionable among treatment seekers. The urinalysis with cassette test is a quick objective method which is recommended for routine screening.
- 26 June 2009
- Vol. 52 (3) , 217-32
Neurobiology of cannabis addiction.
Cannabis has emerged as a common substance of abuse and dependence and the peculiarities associated with this widely available and used substance has triggered substantial research in this field. The earlier held concept of rather benign nature of this compound as a substance of abuse and dependence has changed as a result of the ongoing clinical and research findings. Cannabis has been found to have multiple physical and mental effects in human beings. But still a lot remains to be answered regarding the basis for the development of dependence on cannabis. However, the discovery of various cannabis receptors and their endogenous and synthetic ligands have added fuel to the ever growing interest in this substance. Various hypotheses have been postulated in this regard based on the findings of both the animal and human studies which serve as potential explanations to the observations. These findings have helped in the better understanding of the issue and have provided substrate for the clinical application.
- 26 June 2009
- Vol. 52 (3) , 217-32
Neurobiology of cannabis addiction.
Cannabis has emerged as a common substance of abuse and dependence and the peculiarities associated with this widely available and used substance has triggered substantial research in this field. The earlier held concept of rather benign nature of this compound as a substance of abuse and dependence has changed as a result of the ongoing clinical and research findings. Cannabis has been found to have multiple physical and mental effects in human beings. But still a lot remains to be answered regarding the basis for the development of dependence on cannabis. However, the discovery of various cannabis receptors and their endogenous and synthetic ligands have added fuel to the ever growing interest in this substance. Various hypotheses have been postulated in this regard based on the findings of both the animal and human studies which serve as potential explanations to the observations. These findings have helped in the better understanding of the issue and have provided substrate for the clinical application.
- 4 October 2008
- Vol. 52 (1) , 53-63
Assessment of differential doses of buprenorphine for long term pharmacotherapy among opiate dependent subjects.
The aim of the present study was to evaluate, two different doses of sublingual buprenorphine (2 mg and 4 mg) among patients on maintenance treatment and to assess the relationship of steady state plasma level with craving. Twenty three male opioid dependent (ICD-10 DCR) subjects, were assigned to double blind randomized controlled trial of 2 and 4 mg/day doses of buprenorphine in an inpatient setting. They were evaluated thrice (2nd, 7th and 14th day) in 2 weeks for withdrawal symptoms (acute and protracted), sedation, euphoria, craving, side effects, global rating of well being and for measurement of plasma levels of buprenorphine. The data showed that there were no significant difference in scores of euphoria and sedation, protracted withdrawal symptoms and side effects, craving and overall well being and plasma level of buprenorphine among the subjects. However, both the groups had significant difference in score on almost all the measurements on final observation in comparison to initial observation. Both 2 mg/day and 4 mg/day dose of buprenorphine were effective in long term pharmacotherapy of opioid dependence without significant difference as compared by different measures used in the study.
- 4 October 2008
- Vol. 52 (1) , 53-63
Assessment of differential doses of buprenorphine for long term pharmacotherapy among opiate dependent subjects.
The aim of the present study was to evaluate, two different doses of sublingual buprenorphine (2 mg and 4 mg) among patients on maintenance treatment and to assess the relationship of steady state plasma level with craving. Twenty three male opioid dependent (ICD-10 DCR) subjects, were assigned to double blind randomized controlled trial of 2 and 4 mg/day doses of buprenorphine in an inpatient setting. They were evaluated thrice (2nd, 7th and 14th day) in 2 weeks for withdrawal symptoms (acute and protracted), sedation, euphoria, craving, side effects, global rating of well being and for measurement of plasma levels of buprenorphine. The data showed that there were no significant difference in scores of euphoria and sedation, protracted withdrawal symptoms and side effects, craving and overall well being and plasma level of buprenorphine among the subjects. However, both the groups had significant difference in score on almost all the measurements on final observation in comparison to initial observation. Both 2 mg/day and 4 mg/day dose of buprenorphine were effective in long term pharmacotherapy of opioid dependence without significant difference as compared by different measures used in the study.
- 29 February 2008
- Published by Elsevier in Pharmacology Biochemistry and Behavior
- Vol. 88 (4) , 473-480
Effects of nitric oxide synthase inhibitors in attenuating nicotine withdrawal in rats
- 29 February 2008
- Published by Elsevier in Pharmacology Biochemistry and Behavior
- Vol. 88 (4) , 473-480
Effects of nitric oxide synthase inhibitors in attenuating nicotine withdrawal in rats
- Open Access
- 1 January 2008
- Published by XMLink in Yonsei Medical Journal
- Vol. 49 (2) , 175-188
The Role of NMDA Receptor Antagonists in Nicotine Tolerance, Sensitization, and Physical Dependence: A Preclinical Review
Jain R, et al. Yonsei Med J. 2008 Apr;49(2):175-188. https://doi.org/10.3349/ymj.2008.49.2.175
- 1 January 2008
- Published by XMLink in Yonsei Medical Journal
- Vol. 49 (2) , 175-188
Open AccessThe Role of NMDA Receptor Antagonists in Nicotine Tolerance, Sensitization, and Physical Dependence: A Preclinical Review
Jain R, et al. Yonsei Med J. 2008 Apr;49(2):175-188. https://doi.org/10.3349/ymj.2008.49.2.175
- 1 May 2005
- Published by Elsevier in Brain Research Bulletin
- Vol. 65 (5) , 415-421
Caffeine induces differential cross tolerance to the amphetamine-like discriminative stimulus effects of dopaminergic agonists
- 1 May 2005
- Published by Elsevier in Brain Research Bulletin
- Vol. 65 (5) , 415-421
Caffeine induces differential cross tolerance to the amphetamine-like discriminative stimulus effects of dopaminergic agonists
- 1 December 2004
- Published by Elsevier in Brain Research Bulletin
- Vol. 64 (4) , 319-322
Influence of sweet tasting solutions on opioid withdrawal
- 1 December 2004
- Published by Elsevier in Brain Research Bulletin
- Vol. 64 (4) , 319-322
Influence of sweet tasting solutions on opioid withdrawal
- 1 January 2004
- Vol. 48 (1) , 101-5
Self-reported drug use and urinalysis results.
The study examined the consistency between retrospective self-reported drug use and urinalysis data among 281 male opioid dependent subjects attending out patient clinic of National Drug Dependence Treatment Centre from January 2001 to December 2001 at All India Institute of Medical Sciences, New Delhi. Preliminary analysis indicated that there was moderate to high concordance between the two measures among different drug types. On an average 85% of urine test results matched with self-report. Subject's over-reported drug use as indicated by the low positive predictive value. In contrast, subjects were more accurate when they were reporting no drug use as suggested by the high negative predictive value. The study suggests that urine analysis is a critical variable in substance abuse treatment programs. Clinicians should be cautious while prescribing agonist drug due to frequent over-reporting of drug use by patients in our setting. This will make the substance abuse program more meaningful.
- 1 January 2004
- Vol. 48 (1) , 101-5
Self-reported drug use and urinalysis results.
The study examined the consistency between retrospective self-reported drug use and urinalysis data among 281 male opioid dependent subjects attending out patient clinic of National Drug Dependence Treatment Centre from January 2001 to December 2001 at All India Institute of Medical Sciences, New Delhi. Preliminary analysis indicated that there was moderate to high concordance between the two measures among different drug types. On an average 85% of urine test results matched with self-report. Subject's over-reported drug use as indicated by the low positive predictive value. In contrast, subjects were more accurate when they were reporting no drug use as suggested by the high negative predictive value. The study suggests that urine analysis is a critical variable in substance abuse treatment programs. Clinicians should be cautious while prescribing agonist drug due to frequent over-reporting of drug use by patients in our setting. This will make the substance abuse program more meaningful.
- 1 October 2003
- Vol. 47 (4) , 407-14
Blocking of enhanced sensitivity to behavioral effects of naloxone induced by narcotic agonists in rats.
The present experiment evaluated whether prior treatment with naloxone could block the sensitization to opiate antagonist induced by single dose administration of pure agonist (morphine) or mixed agonist (buprenorphine). Food deprived male Wistar rats were trained to respond for food on a multiple-trial, fixed-interval 3 min schedule. Reinforcement was contingent upon a response within a 10-s limited hold period following a fixed-interval of 3 min. A trial consisted of three fixed interval of 3 min separated by a 10 min timeout period during which responses were not reinforced. The rate decreasing effects of the opioid antagonist naloxone was determined by cumulative dosing. Pretreatment with morphine (0.3 mg/ kg, SC) and buprenorphine (0.03 mg/kg, SC) resulted in an increase sensitivity to the rate decreasing effect of naloxone compared to saline pretreatment. Administration of naloxone (0.3 mg/kg) 10 min prior to pretreatment doses of buprenorphine (0.03 mg/kg; 1.0 mg/kg) and morphine (0.3 mg/kg) increased sensitization to naloxone. However, greater sensitization was observed at low dose of buprenorphine. The increased sensitivity was partially blocked at high dose of buprenorphine (1.0 mg/ kg) by naloxone pretreatment. These results suggest that the doses of naloxone used to block opioid induced sensitization might be different from those required in animals with normal sensitivity to opioid antagonists. Further agonist-induced sensitization to behavioral effects of opioid antagonist appears to be opioid receptor specific.
- 1 October 2003
- Vol. 47 (4) , 407-14
Blocking of enhanced sensitivity to behavioral effects of naloxone induced by narcotic agonists in rats.
The present experiment evaluated whether prior treatment with naloxone could block the sensitization to opiate antagonist induced by single dose administration of pure agonist (morphine) or mixed agonist (buprenorphine). Food deprived male Wistar rats were trained to respond for food on a multiple-trial, fixed-interval 3 min schedule. Reinforcement was contingent upon a response within a 10-s limited hold period following a fixed-interval of 3 min. A trial consisted of three fixed interval of 3 min separated by a 10 min timeout period during which responses were not reinforced. The rate decreasing effects of the opioid antagonist naloxone was determined by cumulative dosing. Pretreatment with morphine (0.3 mg/ kg, SC) and buprenorphine (0.03 mg/kg, SC) resulted in an increase sensitivity to the rate decreasing effect of naloxone compared to saline pretreatment. Administration of naloxone (0.3 mg/kg) 10 min prior to pretreatment doses of buprenorphine (0.03 mg/kg; 1.0 mg/kg) and morphine (0.3 mg/kg) increased sensitization to naloxone. However, greater sensitization was observed at low dose of buprenorphine. The increased sensitivity was partially blocked at high dose of buprenorphine (1.0 mg/ kg) by naloxone pretreatment. These results suggest that the doses of naloxone used to block opioid induced sensitization might be different from those required in animals with normal sensitivity to opioid antagonists. Further agonist-induced sensitization to behavioral effects of opioid antagonist appears to be opioid receptor specific.
- 1 September 2003
- Published by Wolters Kluwer Health in Indian Journal of Pharmacology
- Vol. 35 (5) , 281-289
BIOLOGICAL BASIS OF NICOTINE ADDICTION
Nicotine, the primary component of tobacco produces reinforcing effects both in humans and animals. The neurochemical, anatomical and molecular basis of nicotine dependence is very similar to the other drugs of abuse, particularly the psychostimulants. Nicotine has specific acetylcholine receptors (nAChRs) in the brain and other organs. The stimulation of presynaptic acetylcholine receptors increases transmitter release as well as the metabolism. Nicotine, like other drugs of abuse triggers the dopamine reward system and increases the extracellular level of dopamine in nucleus accumbens (NAc), which is thought to be responsible for the reinforcing behavior, stimulant and dependence properties of nicotine. Nicotine also exerts its effect in the brain on non-dopaminergic structures that may account for its positive rewarding effects and some of the symptoms of nicotine withdrawal. Moreover, the actions of nicotine on many systems, including brain stem cholinergic, GABAergic, noradrenergic, and serotonergic nuclei, may also help to mediate nicotine effects related to addiction. Further, the neurochemical pathway to nicotine reinforcement is likely to be due to binding of nicotine to nAChRs containing the β 2 subunit, followed by activation of the mesolimbic dopamine system and an initiation of common molecular changes that underlie drug dependence. Furthermore, the constituents in tobacco inhibit both forms of the enzyme monoamine oxidase (MAO-A and MAO-B). This enzyme is important in the breakdown of the amine neurotransmitters, including dopamine, which is thought to mediate the reinforcing effects of nicotine and contribute to tobacco dependence. Several questions remain regarding nicotine addiction and further research is needed in this direction. Molecular genetic techniques, coupled with behavioral analysis, may prove to be very useful tools for addressing these questions in near future.
- 1 September 2003
- Published by Wolters Kluwer Health in Indian Journal of Pharmacology
- Vol. 35 (5) , 281-289
BIOLOGICAL BASIS OF NICOTINE ADDICTION
Nicotine, the primary component of tobacco produces reinforcing effects both in humans and animals. The neurochemical, anatomical and molecular basis of nicotine dependence is very similar to the other drugs of abuse, particularly the psychostimulants. Nicotine has specific acetylcholine receptors (nAChRs) in the brain and other organs. The stimulation of presynaptic acetylcholine receptors increases transmitter release as well as the metabolism. Nicotine, like other drugs of abuse triggers the dopamine reward system and increases the extracellular level of dopamine in nucleus accumbens (NAc), which is thought to be responsible for the reinforcing behavior, stimulant and dependence properties of nicotine. Nicotine also exerts its effect in the brain on non-dopaminergic structures that may account for its positive rewarding effects and some of the symptoms of nicotine withdrawal. Moreover, the actions of nicotine on many systems, including brain stem cholinergic, GABAergic, noradrenergic, and serotonergic nuclei, may also help to mediate nicotine effects related to addiction. Further, the neurochemical pathway to nicotine reinforcement is likely to be due to binding of nicotine to nAChRs containing the β 2 subunit, followed by activation of the mesolimbic dopamine system and an initiation of common molecular changes that underlie drug dependence. Furthermore, the constituents in tobacco inhibit both forms of the enzyme monoamine oxidase (MAO-A and MAO-B). This enzyme is important in the breakdown of the amine neurotransmitters, including dopamine, which is thought to mediate the reinforcing effects of nicotine and contribute to tobacco dependence. Several questions remain regarding nicotine addiction and further research is needed in this direction. Molecular genetic techniques, coupled with behavioral analysis, may prove to be very useful tools for addressing these questions in near future.